OBJECTIVE Thyroglobulin measurement is the cornerstone of modern management of differentiated thyroid cancer, with clinical decisions on treatment and follow-up based on the results of such measurements. However, numerous factors need to be considered regarding measurement with and interpretation of thyroglobulin assay results. DESIGN The present document provides an integrated update to the 2013 and 2014 separate clinical position papers of our group on these issues. METHODS Issues concerning analytical and clinical aspects of highly-sensitive thyroglobulin measurement will be reviewed and discussed based on an extensive analysis of the available literature. RESULTS Thyroglobulin measurement remains a highly complex process with many pitfalls and major sources of interference, especially anti-thyroglobulin antibodies, need to be assessed, considered and, when necessary, dealt with appropriately. CONCLUSIONS Our expert consensus group formulated 53 practical, graded recommendations for guidance on highly-sensitive thyroglobulin and TgAb in laboratory and clinical practice, especially valuable where current guidelines do not offer sufficient guidance.

中文翻译：

---

甲状腺球蛋白和甲状腺球蛋白抗体：更新的临床和实验室专家共识。

目的 甲状腺球蛋白测量是分化型甲状腺癌现代治疗的基石，临床治疗和随访决策基于此类测量结果。然而，在甲状腺球蛋白测定结果的测量和解释方面需要考虑许多因素。设计 本文件对我们小组关于这些问题的 2013 年和 2014 年单独临床立场文件进行了综合更新。方法 将根据对现有文献的广泛分析，对有关高灵敏度甲状腺球蛋白测量的分析和临床方面的问题进行回顾和讨论。结果甲状腺球蛋白测量仍然是一个高度复杂的过程，存在许多陷阱和主要干扰源，特别是抗甲状腺球蛋白抗体，需要进行评估、考虑，并在必要时进行适当处理。结论 我们的专家共识小组制定了 53 条实用的分级建议，用于指导实验室和临床实践中的高敏感性甲状腺球蛋白和 TgAb，在当前指南未提供足够指导的情况下尤其有价值。